Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Jennifer M T A MeessenYingjun JiangBillie NowakBethany QiangNancy ChengYuling ChenWilliam Plunkett

Published in: Cancer chemotherapy and pharmacology (2017)

This study provides mechanistic rationales for combining CNDAC with PARP inhibitors, platinum compounds and taxanes in ovarian cancer lacking BRCA1/2 function.

Keyphrases

dna damage
breast cancer risk
cancer therapy
emergency department
drug delivery
adverse drug